Enanta Pharmaceuticals | ENTA - Des Atouts





Des Atouts Changement Date
AbbVie USD 135.12B 1.35B 2026-06
Amgen USD 95.64B 3.14B 2026-06
Anika Therapeutics USD 183.47M 4.09M 2026-06
Arrowhead Research USD 2.11B 156.25M 2026-06
AstraZeneca USD 115.83B 1.82B 2026-06
BioCryst Pharmaceuticals USD 557.85M 92.8M 2026-06
Biogen USD 32.09B 2.6B 2026-06
Bristol-Myers Squibb USD 87.63B 1.16B 2026-06
Enanta Pharmaceuticals USD 329.5M 48.77M 2025-12
Gilead Sciences USD 49.36B 6.92B 2026-06
GlaxoSmithKline GBP 61.74B 1.13B 2026-06
Halozyme Therapeutics USD 2.58B 95.31M 2026-06
Heron Therapeutics USD 252.26M 6.05M 2026-06
Immunic USD 189.74M 165.69M 2026-03
Incyte USD 7.87B 533.53M 2026-06
Insmed USD 2.1B 26.7M 2026-06
Ionis Pharmaceuticals USD 2.99B 455.5M 2026-06
J&J USD 201.06B 167M 2026-06
Karyopharm Therapeutics USD 131.42M 23M 2026-03
Ligand Pharmaceuticals USD 2.19B 653.77M 2026-06
Merck USD 129.8B 1.12B 2026-06
Neurocrine Biosciences USD 5.36B 452.9M 2026-06
Novartis USD 122.03B 3.5B 2026-06
Novavax USD 955.58M 87.59M 2026-06
Pfizer USD 201.13B 6.49B 2026-06
PTC Therapeutics USD 3.25B 381.37M 2026-06
Roche Holding CHF 98.2B 2.5B 2026-06
Sarepta Therapeutics USD 3.19B 9.58M 2026-06
Vertex Pharmaceuticals USD 27.42B 938.9M 2026-06